ATE457169T1 - Verbindungen für die behandlung von gewichtsverlust - Google Patents

Verbindungen für die behandlung von gewichtsverlust

Info

Publication number
ATE457169T1
ATE457169T1 AT99947762T AT99947762T ATE457169T1 AT E457169 T1 ATE457169 T1 AT E457169T1 AT 99947762 T AT99947762 T AT 99947762T AT 99947762 T AT99947762 T AT 99947762T AT E457169 T1 ATE457169 T1 AT E457169T1
Authority
AT
Austria
Prior art keywords
patient
receptor antagonist
weight loss
inhibitor
administering
Prior art date
Application number
AT99947762T
Other languages
English (en)
Inventor
Stefan Anker
Andrew Coats
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9822459.5A external-priority patent/GB9822459D0/en
Priority claimed from GBGB9822458.7A external-priority patent/GB9822458D0/en
Priority claimed from GBGB9917181.1A external-priority patent/GB9917181D0/en
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE457169T1 publication Critical patent/ATE457169T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT99947762T 1998-10-15 1999-10-15 Verbindungen für die behandlung von gewichtsverlust ATE457169T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9822459.5A GB9822459D0 (en) 1998-10-15 1998-10-15 Method of treatment
GBGB9822458.7A GB9822458D0 (en) 1998-10-15 1998-10-15 Methods of treatment
GBGB9917181.1A GB9917181D0 (en) 1999-07-23 1999-07-23 Methods of treatment
PCT/GB1999/003302 WO2000021509A2 (en) 1998-10-15 1999-10-15 Methods of treatment

Publications (1)

Publication Number Publication Date
ATE457169T1 true ATE457169T1 (de) 2010-02-15

Family

ID=27269516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947762T ATE457169T1 (de) 1998-10-15 1999-10-15 Verbindungen für die behandlung von gewichtsverlust

Country Status (9)

Country Link
US (2) US7417038B1 (de)
EP (1) EP1121111B1 (de)
JP (1) JP2002527378A (de)
AT (1) ATE457169T1 (de)
CY (1) CY1110282T1 (de)
DE (1) DE69942009D1 (de)
DK (1) DK1121111T3 (de)
PT (1) PT1121111E (de)
WO (1) WO2000021509A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (de) * 1998-10-15 2010-02-10 Imperial Innovations Limited Verbindungen für die behandlung von gewichtsverlust
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
PL1689378T3 (pl) 2003-12-02 2009-09-30 Sanol Arznei Schwarz Gmbh Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP2305352A1 (de) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
KR101123549B1 (ko) 2004-11-01 2012-04-18 아밀린 파마슈티칼스, 인크. 비만 및 관련 장애의 치료
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
EP1916239A4 (de) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Pyridolverbindung
EP1922336B1 (de) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
IE20050723A1 (en) * 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
EP2072519A4 (de) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diarylketiminderivat
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2145884B1 (de) 2007-04-02 2014-08-06 Msd K.K. Indoledionderivat
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (de) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamidderivat mit antagonistischer wirkung auf rezeptor des melaninkonzentrierenden hormons
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009149493A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
US8946284B2 (en) 2008-08-01 2015-02-03 Arca Biopharma, Inc. Methods and compositions involving (S)-bucindolol
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
GB0907350D0 (en) * 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
RS58234B1 (sr) 2010-01-14 2019-03-29 Novartis Ag Upotreba agensa za modifikovanje hormona adrenalina
IN2012DN06588A (de) 2010-02-10 2015-10-23 Novartis Ag
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MA34916B1 (fr) 2011-02-25 2014-02-01 Merck Sharp & Dohme Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
KR20130074808A (ko) * 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
PL2968226T3 (pl) * 2013-03-14 2019-03-29 Actimed Therapeutics Ltd Kompozycje oksprenololu do leczenia raka
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
EP2832357A1 (de) * 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selektive AT2-Rezeptoragonisten zur Verwendung bei der Behandlung von Kachexie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
US11096908B2 (en) 2016-02-26 2021-08-24 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
EP3558298A4 (de) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetische spirochromanverbindungen
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) * 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) * 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
EP0519925A1 (de) * 1989-11-21 1992-12-30 Sepracor, Inc. Verwendung von optisch reinem s(-)-atenolol zur behandlung kardiovaskulärer erkrankungen
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
PT808172E (pt) 1995-02-10 2003-11-28 Searle & Co Combinacao de inibidor da enzima de conversao da angiotensina e de antagonista de aldosterona para o tratamento de hipertrofia ventricular
JPH0971586A (ja) 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
GB9714675D0 (en) 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
EP1121111B1 (de) * 1998-10-15 2010-02-10 Imperial Innovations Limited Verbindungen für die behandlung von gewichtsverlust
PT1252158E (pt) * 2000-01-31 2005-09-30 Pfizer Prod Inc Derivados heterociclilo benzo-condensado de nicotinamida uteis como inibidores selectivos de isozimas pde4
EP1383496B1 (de) * 2001-02-20 2008-10-01 Dinan, Timothy Gerard Behandlung von fibromyalgie mit pindolol
EP1793818A2 (de) 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol zur behandlung des prämenstruellen syndroms und von prämenstrueller dysphorie
CN101065014A (zh) 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20090215852A1 (en) 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
KR101463724B1 (ko) 2006-11-09 2014-11-21 베링거 인겔하임 인터내셔날 게엠베하 Ｓｇｌｔ-2 억제제를 사용한 병용 치료법 및 이의 약제학적 조성물
KR101546977B1 (ko) 2007-04-24 2015-08-24 아카시아 파마 리미티드 근육 손실의 치료에서의 약물 조합 및 그것의 용도
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies

Also Published As

Publication number Publication date
DK1121111T3 (da) 2010-05-31
US7417038B1 (en) 2008-08-26
PT1121111E (pt) 2010-05-17
US20090023639A1 (en) 2009-01-22
EP1121111B1 (de) 2010-02-10
WO2000021509A2 (en) 2000-04-20
JP2002527378A (ja) 2002-08-27
WO2000021509A3 (en) 2000-11-09
DE69942009D1 (de) 2010-03-25
US7829596B2 (en) 2010-11-09
EP1121111A2 (de) 2001-08-08
CY1110282T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
ATE457169T1 (de) Verbindungen für die behandlung von gewichtsverlust
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
AU2003268144A8 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
MXPA05007381A (es) Metodo para el tratamiento de transtornos funcionales del intestino.
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
ATE401913T1 (de) Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation
ATE370738T1 (de) Verwendung von eplerenon zur behandlung von restenose
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE353886T1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
DE60017793D1 (de) Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121111

Country of ref document: EP